Literature DB >> 15650495

Predictors of treatment nonresponse in bipolar children and adolescents with manic or mixed episodes.

Gabriele Masi1, Giulio Perugi, Cristina Toni, Stefania Millepiedi, Maria Mucci, Nicoletta Bertini, Hagop S Akiskal.   

Abstract

Even though juvenile bipolar disorder (BD) is reported to be more treatment-resistant than adult BD, predictors of nonresponse are not well studied. The aim of this study was to address this issue in a naturalistic sample of bipolar children and adolescents with manic or mixed episodes treated under the condition of routine clinical practice. This study was comprised of 40 patients (19 females and 21 males; mean age, 14.2 years; SD = 3.3; range, 7-18) with a Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) diagnosis of manic (n = 23) or mixed episodes (n = 17). The clinical characteristics of 20 patients considered to be treatment responders, according to the Clinical Global Impression-Improvement (CGI-I) scores, were compared to those of the 20 nonresponders. The effect of predictors on the probability of treatment nonresponse was analyzed using the multiple stepwise logistic regression, backward procedure. Demographic variables (mean age, gender ratio, socioeconomic status), as well as the inpatients-outpatients ratio (75% versus 65%), duration of the follow-up (10.5 +/- 2.5 months versus 9.6 +/- 3.2 months), index episode (manic versus mixed), and rates of pharmacologic hypomania did not differentiate the 2 groups. According to stepwise logistic regression, predictors of nonresponse were the presence of comorbidity with conduct disorder (odd ratio, 3.36; 95% CI, 2.20-4.52), attention deficit hyperactivity disorder (ADHD) (odd ratio, 2.30; CI, 1.24-3.26), and the baseline CGI Severity score (odd ratio, 2.31; CI, 1.33-3.29). It is relevant to point out that patient age at the onset of BD, and at the first visit, and comorbid anxiety disorders did not influence treatment response. Follow-up studies with a larger sample size with BD and/or externalizing disorders appropriately managed with different treatment options and/or combinations are warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650495     DOI: 10.1089/cap.2004.14.395

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  7 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

2.  Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.

Authors:  Amy E West; Sally M Weinstein; Christine I Celio; David Henry; Mani N Pavuluri
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-02       Impact factor: 2.576

3.  Database analysis of children and adolescents with bipolar disorder consuming a micronutrient formula.

Authors:  Julia J Rucklidge; Dermot Gately; Bonnie J Kaplan
Journal:  BMC Psychiatry       Date:  2010-09-28       Impact factor: 3.630

4.  Neurocognition in bipolar disorder and juvenile bipolar disorder.

Authors:  Catherine M Cahill; Garry Walter; Gin S Malhi
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-08

5.  Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study.

Authors:  Gabriele Masi; Annarita Milone; Azzurra Manfredi; Cinzia Pari; Antonella Paziente; Stefania Millepiedi
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder.

Authors:  Gabriele Masi; Simone Pisano; Chiara Pfanner; Annarita Milone; Azzurra Manfredi
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-10       Impact factor: 2.576

7.  Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight.

Authors:  Robert L Findling; Willie Earley; Trisha Suppes; Mehul Patel; Xiao Wu; Cheng-Tao Chang; Roger S McIntyre
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-02       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.